| Literature DB >> 22691718 |
Shailesh V Jain1, Manjunath Ghate, Kamlendra S Bhadoriya, Sanjaykumar B Bari, Amar Chaudhari, Jayshri S Borse.
Abstract
BACKGROUND: The discovery of clinically relevant inhibitors of HIV-RT for antiviral therapy has proven to be a challenging task. To identify novel and potent HIV-RT inhibitors, the quantitative structure-activity relationship (QSAR) approach became very useful and largely widespread technique forligand-based drug design.Entities:
Year: 2012 PMID: 22691718 PMCID: PMC3495901 DOI: 10.1186/2191-2858-2-22
Source DB: PubMed Journal: Org Med Chem Lett ISSN: 2191-2858
Molecular structures of compounds and their NNRT inhibitory activity
| 7a1 | H | H | Cl | H | 26.11 | 4.58 |
| 7a4 | H | H | Br | H | 22.42 | 4.64 |
| 7a5a | H | H | Br | CH3 | 13.73 | 4.86 |
| 7a6a | H | H | Br | CO2C2H5 | 5.21 | 5.28 |
| 7a7 | H | H | Br | CO2CH3 | 5.1 | 5.29 |
| 7b1a | H | OMe | Cl | H | 2.63 | 5.58 |
| 7b2 | H | OMe | NO2 | H | 0.99 | 6 |
| 7b4a | H | OMe | Br | H | 3.19 | 5.49 |
| 7b5a | H | OMe | Br | CH3 | 5.06 | 5.29 |
| 7b6 | H | OMe | Br | CO2C2H5 | 3.01 | 5.52 |
| 7b7a | H | OMe | Br | CO2CH3 | 2 | 5.69 |
| 7c1 | F | F | Cl | H | 1.23 | 5.91 |
| 7c2 | F | F | NO2 | H | 4.14 | 5.38 |
| 7c3a | F | F | F | H | 5.45 | 5.26 |
| 7c4 | F | F | Br | H | 2.26 | 5.64 |
| 7c5a | F | F | Br | CH3 | 1.45 | 5.83 |
| 7d1a | Cl | Cl | Cl | H | 0.12 | 6.92 |
| 7d2 | Cl | Cl | NO2 | H | 0.06 | 7.22 |
| 7d3 | Cl | Cl | F | H | 0.14 | 6.86 |
| 7d4 | Cl | Cl | Br | H | 0.15 | 6.82 |
| 7d5a | Cl | Cl | Br | CH3 | 0.2 | 6.69 |
| 7d6 | Cl | Cl | Br | CO2C2H5 | 0.1 | 7 |
aTest compounds set.
Uni-column statistics of the training and test sets for QSAR models
| 2D-QSAR | ||||||
| Training | pEC50(μM) | 5.9092 | 7.2300 | 4.5800 | 0.9019 | 70.9100 |
| Test | pEC50(μM) | 5.6940 | 6.9300 | 4.8600 | 0.6500 | 56.9400 |
| 3D-QSAR | ||||||
| Training | pEC50(μM) | 5.8417 | 7.2300 | 4.5800 | 0.7859 | 105.1500 |
| Test | pEC50(μM) | 5.6750 | 6.9300 | 4.8600 | 0.8967 | 22.7000 |
Figure 1Comparison of observed activity versus predicted activity for training set & test set compounds according to 2D-QSAR model.
Figure 2Contribution of descriptors for biological activity developed using MLR equation.
Descriptors used in 2D & 3D-QSAR models with values
| 7a1 | 5 | 16.12701 | 0 | 4.951941 | 0.337546 | 0.088079 |
| 7a4 | 5 | 22.34026 | 0 | 5.241149 | 0.340001 | 0.109635 |
| 7a5a,b | 6 | 16.34572 | 0 | 4.63805 | 0.353856 | 0.057851 |
| 7a6a | 6 | 3.079616 | 0 | 4.141958 | 0.342394 | 0.136266 |
| 7a7 | 6 | −26.8322 | 0 | 7.462867 | 0.334305 | 0.117725 |
| 7b1a | 6 | 10.24981 | 0 | 5.100435 | 0.350985 | 0.049167 |
| 7b2 | 6 | 30.74947 | 0 | 8.220488 | 0.332967 | 0.027609 |
| 7b4a | 6 | −38.4946 | 0 | 5.790629 | 0.345013 | 0.141681 |
| 7b5a | 7 | 12.74566 | 0 | 5.113997 | 0.369819 | −0.030558 |
| 7b6 | 7 | −41.4985 | 0 | 6.625907 | 0.358049 | 0.154737 |
| 7b7a | 7 | −17.1541 | 0 | 5.913619 | 0.345649 | 0.196553 |
| 7c1 | 7 | −13.5687 | 0 | 7.263344 | 0.368474 | −0.008455 |
| 7c2 | 7 | −46.9851 | 0 | 5.258711 | 0.329492 | −0.064939 |
| 7c3a,b | 7 | −13.251 | 0 | 5.105986 | 0.335960 | −0.034363 |
| 7c4b | 7 | −10.3413 | 0 | 5.992268 | 0.369205 | 0.042498 |
| 7c5a | 8 | −5.89083 | 0 | 6.29995 | 0.398119 | 0.028883 |
| 7d1a,b | 7 | −6.89132 | 2 | 6.834099 | 0.463411 | 0.019026 |
| 7d2 | 7 | 18.5915 | 2 | 6.196837 | 0.428789 | −0.072705 |
| 7d3 | 7 | −9.69926 | 2 | 6.197515 | 0.429396 | −0.019153 |
| 7d4 | 7 | 36.29885 | 2 | 5.712653 | 0.437677 | −0.026282 |
| 7d5a | 8 | −24.2613 | 2 | 4.75547 | 0.497335 | −0.003169 |
| 7d6 | 8 | −12.1663 | 2 | 5.933494 | 0.478959 | −0.006141 |
aThe compounds considered in the test set in 2D QSAR.
bThe compounds considered in the test set in 3D QSAR.
Observed, predicted activity, and residual values of statistically significantly models obtained by MLR & kNN-MFA
| 7a1 | 4.58 | 4.46 | 0.12 | 4.97 | −0.39 |
| 7a4 | 4.64 | 4.59 | 0.5 | 4.94 | −0.30 |
| 7a5a,b | 4.86 | 4.99 | 0.13 | 5.08 | −0.15 |
| 7a6a | 5.28 | 4.74 | 0.46 | 5.39 | −0.11 |
| 7a7 | 5.29 | 5.33 | 0.4 | 4.96 | 0.33 |
| 7b1a | 5.58 | 5.05 | 0.53 | 5.30 | 0.28 |
| 7b2 | 6 | 6.038 | −0.38 | 5.74 | 0.26 |
| 7b4a | 5.49 | 4.80 | −0.31 | 5.40 | 0.9 |
| 7b5a | 5.29 | 5.68 | −0.39 | 5.65 | −0.36 |
| 7b6 | 5.52 | 5.60 | −0.8 | 5.39 | 0.13 |
| 7b7a | 5.69 | 5.63 | 0.6 | 5.51 | 0.18 |
| 7c1 | 5.91 | 6.01 | −0.10 | 5.57 | 0.34 |
| 7c2 | 5.38 | 5.20 | 0.18 | 5.60 | −0.22 |
| 7c3a,b | 5.26 | 5.45 | 0.19 | 5.34 | −0.8 |
| 7c4b | 5.64 | 5.71 | −0.7 | 5.70 | −0.6 |
| 7c5a | 5.83 | 6.43 | 0.40 | 5.75 | 0.8 |
| 7d1a,b | 6.92 | 6.92 | 0 | 6.84 | 0.8 |
| 7d2 | 7.22 | 6.97 | 0.25 | 6.85 | 0.37 |
| 7d3 | 6.86 | 6.73 | 0.13 | 6.91 | −0.5 |
| 7d4 | 6.82 | 7 | 0.18 | 6.93 | −0.11 |
| 7d5a | 6.69 | 6.83 | −0.14 | 6.92 | −0.23 |
| 7d6 | 7 | 7.24 | −0.24 | 6.76 | 0.24 |
aThe compounds considered in the test set in 2D QSAR.
bThe compounds considered in the test set in 3D QSAR.
Statistical results of 2D QSAR equation generated by MLR method and 3D QSAR models generated by forward stepwise variable selection kNN MFA method for 1,2,3-thiadiazole thioacetanilides derivatives
| 1 | 0.97 | – | |
| 2 | 0.19 | – | |
| 3 | 0.94 | 0.89 | |
| 4 | 0.29 | 0.26 | |
| 5 | pred_ | 0.62 | 0.97 |
| 6 | pred_ | 0.43 | 0.15 |
| 7 | 60.77 | – | |
| 8 | 12 | 18 | |
| 9 | Nearestneighbor | – | 2 |
| 10 | Degree of freedom | 7 | 15 |
| 11 | Contributing descriptors | SaasCcount (36.12%) | H_171 (0.429396, 0.437677) |
Figure 3Comparison of observed activity versus predicted activity for training set and test set compounds according to 3D-QSAR model.
Figure 4Stereo view of the molecular rectangular field grid around the superposed molecular units of 1,2,3-thiadiazole thioacetanilides series of compounds using SW-kNN MFA method.
Results of molecular docking
| 1 | 7d1 | −12.29 | −7.22 | −0.65 | 0.01 |
| 2 | Efavirenz | −11.61 | −5.59 | −0.7 | −0.21 |
| 3 | 7c5 | −11.29 | −6.7 | −0.7 | −0.36 |
| 4 | 7c4 | −11.17 | −6.53 | −0.7 | −0.35 |
| 5 | 7d3 | −11.09 | −7.6 | −0.51 | −0.11 |
| 6 | 7d4 | −10.97 | −7.99 | 0 | −0.11 |
| 7 | 7c3 | −10.95 | −6.51 | −0.7 | −0.2 |
| 8 | 7d6 | −10.9 | −6.79 | −0.7 | −0.37 |
| 9 | 7c1 | −10.83 | −6.21 | −0.7 | −0.33 |
| 10 | 7b4 | −10.81 | −6.13 | −0.68 | −0.21 |
| 11 | Zidovudine | −10.81 | −3.68 | −2.17 | −0.47 |
| 12 | 7b1 | −10.75 | −6.03 | −0.7 | −0.25 |
| 13 | 7b2 | −10.75 | −6.77 | −0.57 | 0.12 |
| 14 | 7d5 | −10.6 | −6.93 | −0.7 | −0.38 |
| 15 | 7b5 | −10.46 | −6.17 | −0.6 | −0.2 |
| 16 | 7b6 | −10.38 | −6.65 | −0.7 | −0.36 |
| 17 | 7a7 | −10.33 | −6.74 | −0.7 | −0.3 |
| 18 | 7b7 | −10.15 | −6.58 | −0.7 | −0.25 |
| 19 | 7a1 | −10.15 | −5.46 | −0.61 | −0.19 |
| 20 | 7c2 | −10.13 | −6.27 | −0.67 | −0.16 |
| 21 | 7a5 | −10.05 | −6.67 | −0.7 | −0.44 |
| 23 | 7a4 | −9.98 | −6.52 | −0.7 | −0.37 |
| 24 | 7a6 | −9.92 | −7.37 | 0 | −0.11 |
| 25 | Delavirdine | −9.89 | −7.63 | −1.27 | −0.74 |
| 26 | 7d2 | −9.47 | −6.98 | 0 | −0.05 |
| 27 | Nevirapine | −6.59 | −4.88 | 0 | −0.1 |
Figure 5Binding interaction of compounds with NNRT receptors. (a) Compounds 7c4 interacting with NNRT receptor protein of PDB 1KLM. (b) Compounds 7c5 interacting with NNRT receptor protein of PDB 1KLM. Dotted yellow bond showing H-bond interactions with binding site residues. Grey surface showing lipophilic interaction and brown color showing electrostatic interactions.